MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
6.26
+0.17
+2.79%
After Hours: 6.21 -0.05 -0.80% 18:47 02/06 EST
OPEN
6.22
PREV CLOSE
6.09
HIGH
6.66
LOW
6.00
VOLUME
520.60K
TURNOVER
--
52 WEEK HIGH
10.38
52 WEEK LOW
3.510
MARKET CAP
114.62M
P/E (TTM)
-0.4294
1D
5D
1M
3M
1Y
5Y
1D
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Benzinga · 2d ago
Cantor Fitzgerald Initiates Coverage On Karyopharm Therapeutics with Overweight Rating
Benzinga · 2d ago
Karyopharm Therapeutics Inc. to Report Financial Results
Reuters · 3d ago
Karyopharm Therapeutics Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Reuters · 3d ago
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
PR Newswire · 3d ago
Karyopharm initiated with an Overweight at Cantor Fitzgerald
TipRanks · 3d ago
Karyopharm Therapeutics Grants RSUs to New Employees Under Inducement Plan
Reuters · 5d ago
Weekly Report: what happened at KPTI last week (0126-0130)?
Weekly Report · 6d ago
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.